Novartis taps Akin Gump to lobby in DC; Google shareholder sues over pharmacy ads;

@FiercePharma: Top drugmakers report payments of $150M to 165K docs so far this year, FT finds. Last full year: $437M. Report | Follow @FiercePharma

> Novartis ($NVS) has hired Akin Gump Strauss Hauer & Feld to lobby in Washington about vaccines after spending $3.6 million on lobbying during the first half of this year. News

> Novartis' ($NVS) Alcon unit in the U.S. sued Apotex to block a generic version of the allergy-fighting nasal spray Patanase. Report

> A Google ($GOOG) shareholder has sued the company and its board, claiming they breached fiduciary duties by running the online pharmacy ads that led to a $500 million settlement with the U.S. government. Story

> After investing $650 million in Vodafone and eyeing pharma investments in U.S. and Europe, Piramal is looking at bidding for India's Future Capital, the financial services arm of Future Group. Article

> In Europe, 95% of doctors go online for professional reasons, and the same percentage uses handheld devices to download apps and access medical information. Item

> BASF plans to increase prices for generic APIs and pharmaceutical excipients by 10% beginning Sept. 1. Report

Biotech News

@FierceBiotech: Actelion drug macitentan flunks PhII but safety data bolsters confidence in blockbuster PhIII. News | Follow @FierceBiotech

@JohnCFierce: The Guardian runs down a litany of biotech failures, challenges and ends on a quick 'up' note regarding collaborations. Piece | Follow @JohnCFierce

@RyanMFierce: New Facebook app "PiggyDemic," from scientists at Tel Aviv University, aims to simulate how viruses spread and mutate. Item | Follow @RyanMFierce

@MaureenFierce: Adimab adds Novo, Biogen Idec to roster of antibody partners. Story | Follow @MaureenFierce

> NuPathe shares in meltdown after FDA rejects migraine patch app. Article

> FDA highlights new tech to monitor trials. News

> New R&D culture at GSK forces a challenging showdown. Story

> Niche cancer drugs highlight the targeting trend in R&D. Item 

> U.K.'s biotech stars may be fading, but new hopefuls. Report

> Bleeding risk spikes for Astellas's PhII anticoagulant. Article 

Biotech Research News

> JHU researchers have a full platelet of blood-clotting research. More

> Researchers find new clues into spread of influenza B. News

> A possible solution found for TTR-related amyloid diseases. Report

> So, a needle-pulling-thread is outdated, doc goes sutureless. Article

> Patient in stem-cell treatment for MS reports improvement. Details

> Researchers dream up a new cause for narcolepsy. Story

Manufacturing News

> Sabotage suspected in U.K. painkiller case. News

> Distributor plans to excise supply chain links. Story

> WHO committee report keeps pharma current. Brief

> Abbott taps manufacturing smarts in Haiti rebuild. Details

> Venus warning letter belies poor 483 response. Article

> Time to put the innovation into manufacturing. More

> U.S. tax reform or not, offshore beckons. Report

And Finally... Scientists found a genetic variant linked to liver cancer in hepatitis C carriers. News

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.